Your session is about to expire
← Back to Search
Iron Supplement
Efficacy of a Low Dose, Oral, Liquid Iron Supplement on Restoring Inadequate Blood Iron to Normal Levels
N/A
Waitlist Available
Research Sponsored by Applied Science & Performance Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0, week 4, and week 8
Summary
This trial is testing a new low-dose iron supplement to see if it is safe and effective in restoring iron levels without causing constipation among healthy premenopausal women with iron deficiency.
Eligible Conditions
- Iron Deficiency
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 0, week 4, and week 8
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0, week 4, and week 8
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Complete Blood Count
High Sensitivity C-Reactive Protein (hs-CRP)
Serum Ferritin
+3 moreSecondary study objectives
Abbreviated Profile of Mood States
Adverse Events
Cathartics
+2 moreOther study objectives
Body Composition via Body Fat Percentage
Bone Mineral Density
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Blood Builder TreatmentExperimental Treatment1 Intervention
Daily dose (10 mL) of liquid iron supplement (Blood Builder®) formulation to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
Group II: PlaceboPlacebo Group1 Intervention
Daily dose (10 mL) of a visually identical liquid placebo supplement to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liquid Iron Supplement (Blood Builder ®)
2022
N/A
~100
Find a Location
Who is running the clinical trial?
Applied Science & Performance InstituteLead Sponsor
14 Previous Clinical Trials
799 Total Patients Enrolled